Navigation Links
oral in Medical Technology

Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364

KING OF PRUSSIA, Pa., July 20 /PRNewswire/ -- Cytokine PharmaSciences, Inc. today announced the initiation of a Phase I study of CPSI-2364, its orally active, small-molecule inhibitor of the production of TNF-alpha and other pro-inflammatory cytokines. Results of the dose escalation and...

Is Obesity an Oral Bacterial Disease?

ALEXANDRIA, Va., July 9 /PRNewswire-USNewswire/ -- The world-wide explosion of overweight people has been called an epidemic. The inflammatory nature of obesity is widely recognized. Could it really be an epidemic involving an infectious agent? In this climate of concern over the increasing preval...

School of Dentistry Studies Link Between Oral Health and Memory

MORGANTOWN, W.Va., June 19 /PRNewswire-USNewswire/ -- Keeping your teeth brushed and flossed can cut down on gum disease, drastically reducing risk of heart attack and stroke, dentists have warned for years. Now researchers at West Virginia University have found a clean mouth may also help prese...

Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride: Oral 162

NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- Novo Nordisk (NVO) data presented today at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily liraglutide, taken as monotherapy, leads to statistically significant and sustained reductions in blood sug...

PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference

Oral CCR9 Antagonist Demonstrates Clinical Efficacy with Favorable Tolerability Profile MOUNTAIN VIEW, Calif., June 1 /PRNewswire/ -- ChemoCentryx, Inc., announced that Phase II/III clinical data from the company's PROTECT-1 (the P rospective R andomized O ral T herapy E valuation in ...

Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule

JERUSALEM, May 5 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTC: ORMP) ( http://www.oramed.com ), a developer of oral delivery systems, announced that Phase 2b clinical trials will commence this week on 30 Type 2 Diabetic volunteers. The study is intended to evaluate the safety, t...

Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting

SAN DIEGO, April 17 /PRNewswire/ -- Cylene Pharmaceuticals announced today that it will be presenting new data on recent advances of its small molecule anticancer agents during a symposium and several poster presentations at the American Association for Cancer Research (AACR) annual meeting, to be...

Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line

Only 39 Percent of Newly Diagnosed Patients Receive a Drug Within One Year of Their First Diagnosis, According to a New Report from Decision Resources WALTHAM, Mass., April 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceut...

Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma

SUNNYVALE, Calif., April 13 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced that it has begun treating patients in a Phase 1 dose-escalation study to evaluate the safety and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine ...

New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery

NEW YORK, March 31 /PRNewswire/ -- Transdermal delivery of estrogen therapy available by prescription "seems not to alter" the risk of venous thromboembolism (VTE), or blood clotting, in postmenopausal patients when compared to oral delivery, a new study suggests. The study was conducted by res...

Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)

JERUSALEM, March 25 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral delivery systems, announced today that it has been selected to present the results from the study, entitled, "Open Label Study to Assess the Safety, Pharma...

Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study

A Phase II Study Published in The Lancet of Fast-Tracked Antiplatelet Agent Showed No Increase in TIMI Major and Minor Bleeding and was Well Tolerated When Given With Standard Platelet Therapy KENILWORTH, N.J., March 12 /PRNewswire-FirstCall/ -- Results of a Schering-Plough Corporation (NYSE:...

American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule

NEW YORK, March 9 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB ), a China-based pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") pr...

Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)

Highly Statistically Significant Results Achieved at Two Dose Levels with No Reversal of Analgesia SAN CARLOS, Calif., March 2 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced positive topline results today from a Phase 2 double-blind, randomized, placebo-controlled ...

Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection

PHILADELPHIA, Feb. 12 /PRNewswire-USNewswire/ -- When treating children for acute osteomyelitis--a bacterial bone infection--an early changeover from intravenous (IV) antibiotic delivery to oral antibiotics is just as effective as continuing the IV therapy, according to pediatric researchers. ...

Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997

MELBOURNE, Australia, Feb.5 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has successfully concluded dose-escalation in its oral Phase I study for CYT997, the company's anticancer vascular-disrupting agent (VDA). The primary objectives of this safety and tolerability study have been achieved. T...

Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis

SAN DIEGO, Jan. 22 /PRNewswire/ -- Meritage Pharma, Inc. announced today that it has initiated a dose-ranging Phase 2b clinical trial to evaluate oral viscous budesonide (OVB) for the treatment of children and adolescents with eosinophilic esophagitis (EoE), an allergic inflammatory condition of t...

New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer

-Growing Body of Data Supports XELOX as Effective Alternative to Standard of Care- NUTLEY, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Overall survival results from a 14-month follow-up of the international, Phase III NO16966 study confirm that oral Xeloda(R) plus oxaliplatin (XELOX) is comp...

Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference

CAMBRIDGE, Mass., Jan. 6 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that the company has recently completed a successful toxicology study of its candidate CEQ501, an orally a...

Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention

SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular disease, inflammatory disease and cancer, today announced that it has initiated patient enrollment in INNOVATE-PC...

New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation

SAN FRANCISCO, Dec. 7 /PRNewswire-FirstCall/ -- Patients with non-valvular atrial fibrillation receiving either 30 mg or 60 mg once-daily dose of DU-176b, an investigational oral Factor Xa inhibitor, experienced comparable safety and tolerability compared to those taking warfarin, according to new...

TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients

SAN DIEGO, Dec. 1 /PRNewswire/ -- TargeGen has announced that an oral presentation of preliminary results from a multi-center, US-based clinical trial of TG101348 in myeloproliferative disease patients has been scheduled at the 2008 American Society of Hematology (ASH) Meeting. Details o...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

Company reaffirms its innovation leadership and long-term commitment to hepatitis research KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today provided a clinical update on boceprevir, its lead investigational oral hepatitis C protease inhi...

FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder

PHILADELPHIA, Nov. 20 /PRNewswire-FirstCall/ --GlaxoSmithKline (NYSE: GSK ) today announced that the United States Food and Drug Administration (FDA) granted accelerated approval for PROMACTA(R) (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immu...

Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C

PRINCETON, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ), Roche (SWX: ROG) and InterMune, Inc. (Nasdaq: ITMN ) today announced that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV)....

Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin

SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today announced top-line results from its Phase 1 clinical trial of an oral formulation of picoplatin in patients with solid tumors sho...

Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections

Data to be presented at annual ICAAC/IDSA meeting in Washington, D.C. WASHINGTON, Oct. 28 /PRNewswire/ -- Scientists at NanoBio Corporation have demonstrated for the first time in humans that a novel topical treatment for cold sores (herpes labialis), NB-001, speeds healing of lesions as effe...

Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics

Study to Assess the Safety and Efficacy of ORMD 0801, Oral Insulin Capsule, on Type 1 Diabetics JERUSALEM, Israel, September 24 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral delivery systems, announ...

Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim

REINACH, Switzerland, September 24 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced the completion of enrolment in the Phase II 'intravenous-to-oral' switch trial with oral iclaprim in patients with complicated Skin and Skin Structure Infections (cSSSI). The trial was design...

S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies

SINGAPORE, Sept. 18 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of multi-center Phase I clinical trials of SB1518, a potent and orally-active JAK2 inhibitor, in patients with leukemia and certain types of lymphoma. These first Phase I trials for SB1518 comprise of ascending do...

Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA

EDP-322 is a First-in-class MRSA-active Bicyclolide, a novel macrolide-related drug class WATERTOWN, Mass., Sept. 15 /PRNewswire/ -- Enanta Pharmaceuticals, a leader in the development of small molecule anti-infective drugs, announced today the initiation of a Phase ...

Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b

MUNICH, Germany, Sept. 2 /PRNewswire-FirstCall/ -- Data presented today at the Annual Congress of the European Society of Cardiology showed that the investigational oral Factor Xa inhibitor DU-176b reduced the incidence of venous thromboembolism (VTE) compared with dalteparin among patients un...

Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)

JERUSALEM, Israel, August 18 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of oral delivery systems, announced today that its abstract, entitled "Open Label Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (...

Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule

The Trial Demonstrated the Safety and Efficacy of the ORMD 0801- Oral Insulin Capsule JERUSALEM, Israel, August 6 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP)( http://www.oramed.com ), a developer of oral delivery systems, announced today suc...

Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment

Phase III Study to Explore the Effects of Eligen(R) Delivery Technology and Salmon Calcitonin on Vertebral Fractures in Postmenopausal Women CEDAR KNOLLS, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS ) announced today that Novartis Pharma AG has finished ...

Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials

JERUSALEM, July 31 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP) ( http://www.oramed.com ), a developer of oral delivery systems, announced today that it will hold a conference call on August 6, 2008 at 10:30 AM EDT to present the results of its Phase 2A clinical trials ...

Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations

GLP-1 Has Potential to Treat Type 2 Diabetes Using Emisphere's Eligen(R) Technology CEDAR KNOLLS, N.J., July 8 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS ) today announced findings from a clinical study assessing the oral delivery of GLP...

Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma

HOUSTON, July 1 /PRNewswire/ -- Agennix Incorporated today announced the publication of final results from a Phase 2 monotherapy trial with talactoferrin alfa in patients who had failed previous treatment for advanced or metastatic renal cell carcinoma (RCC). Results from the study, which were...

Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)

Phase I Study to Explore the Effects of Eligen(R) Delivery Technology on Healthy Postmenopausal Women CEDAR KNOLLS, N.J., June 30 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS ) announced today that Novartis Pharma AG has launched a Phase I study in...

FDA Lifts Clinical Hold on Genta's Tesetaxel, a Leading Oral Taxane

Clinical Studies Expected to Restart in Second Half 2008 BERKELEY HEIGHTS, N.J., June 23 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced that the Company has received notification from the U.S. Food and Drug Administration (FDA) that Genta may resume c...
Other Tags
(Date:8/29/2014)... - The rise of the Tibetan plateau -- the ... is important for both its profound effect on climate ... published in GSA Bulletin , Katharine Huntington and ... thermometry -- using modern and fossil snail shells to ... southwestern Tibet. , Views range widely on the ...
(Date:8/28/2014)... is pleased to announce the selection of Dr. Fred ... Membership acknowledges those who have served ESA for at ... of the Society that has reached an extraordinary level. ... Governing Board and then voted on by the ESA ... Ceremony at Entomology 2014, ESA,s Annual Meeting in Portland, ...
(Date:8/28/2014)... A new study reports that an expansion of marine ... perform key ecological functions. According to investigators from ... at protecting fish have focused on saving the largest ... species that provide key and difficult-to-replace ecological functions. ... are performed by fish species that also are food ...
Breaking Biology News(10 mins):Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Fred Baxendale selected as Honorary Member of the Entomological Society of America 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- Astronauts ... travel appears to disrupt human immune systems, a new ... on any long missions to asteroids, the moon and ... or flu while in space can be dangerous, NASA ... immune cells in the blood of International Space Station ...
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- If you have ... more serious treatment later, an expert says. A bunion ... big toe when bone or tissue moves out of place ... untreated, bunions can cause debilitating pain and may require surgery ... at CentraState Medical Center in Freehold, N.J. To prevent ...
(Date:8/29/2014)... IL (PRWEB) August 29, 2014 A ... hearing wellness solutions, is on its way to the ... the San Diego Convention Center to exhibit and demonstrate ... work in high-noise industrial environments. Etymotic’s safety earphones and ... wearable technology devices at the show. , The ...
(Date:8/29/2014)... 2014 LiveOps, Inc., the global leader ... announced that LiveOps has been selected as a call ... of Strength Telethon for the third year in a ... awareness to support MDA’s mission to help children and ... fatal muscle disease. This year’s program includes performances by ...
(Date:8/29/2014)... cancer patients lacking knowledge about the disease have difficulty ... quality of care and long-term results, new research suggests. ... age of 63. All were newly diagnosed with localized ... associated with greater difficulty deciding which treatment to choose ... the study found. "For prostate cancer, there is ...
Breaking Medicine News(10 mins):Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2Health News:Take Steps to Control Bunions 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 3Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 4Health News:Faced With Prostate Cancer, It Helps to Know the Enemy 2
Other Contents